New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
05:12 EDTREGNRegeneron's Eylea Injection approved by European Commission
Regeneron Pharmaceuticals announced that Eylea Injection has been approved by the European Commission for the treatment of patients with neovascular, or wet, age-related macular degeneration, also known as wet AMD. According to the European Medicines Agency, or EMA, approved Summary of Product Characteristics, Eylea treatment is initiated with one 2 mg injection per month for three consecutive months, followed by one injection every two months. There is no requirement for monitoring by the physician between injections. After the first twelve months of treatment with Eylea, the treatment interval may be extended based on visual and anatomic outcomes. In such cases, the frequency of monitoring visits is determined by the treating physician and may be more often than the schedule of injections.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:57 EDTREGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 11, 2014
07:07 EDTREGNRegeneron reports Q2 EPS 9c, consensus 6c
Subscribe for More Information
05:32 EDTREGNRegeneron Eylea injection receives EU approval for DME treatment
Subscribe for More Information
August 7, 2014
17:12 EDTREGNRegeneron reports 8.1% passive stake in Avalanche Biotechnologies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use